FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions refers to pharmaceutics, namely to a pharmaceutical composition for a transdermal therapeutic system for administering alprazolam, containing 0.01 to 5.0 wt%. by weight of the composition of alprazolam, from 30 to 70 wt% of weight of composition of polyvinylpyrrolidone and from 10 to 50 wt% by weight of the composition of a mixture of plasticizers selected from polyethylene glycol 400, ethyl lactate and levulinic acid.
EFFECT: group of inventions provides minimizing the amount of components of the composition containing alprazolam, improved adhesion with skin, stable therapeutically effective concentration of alprazolam for at least 24 hours.
15 cl, 4 dwg, 6 ex, 7 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE | 2019 |
|
RU2798017C2 |
| TRANSDERMAL THERAPEUTIC SYSTEM FOR ADMINISTERING ACTIVE SUBSTANCE BUPRENORPHINE | 2007 |
|
RU2484822C2 |
| TRANSDERMAL PLASTER | 2010 |
|
RU2445123C2 |
| TRANSDERMAL PLASTER | 2010 |
|
RU2445084C2 |
| TOLTERODIN-CONTAINING TRANSDERMAL THERAPEUTIC SYSTEM (TTS) | 2000 |
|
RU2251413C2 |
| TRANSDERMATIC PLASTER WITH GLYCAZIDE | 2019 |
|
RU2736081C1 |
| TRANSDERMAL THERAPEUTIC SYSTEM | 2006 |
|
RU2450805C2 |
| TRANSDERMAL MEMANTINE DELIVERY SYSTEMS | 2017 |
|
RU2764764C2 |
| TRANSDERMAL DONEPEZIL DELIVERY SYSTEM | 2017 |
|
RU2779471C2 |
| TRANSDERMAL ADMINISTRATION OF MEMANTINE | 2011 |
|
RU2578971C2 |
